Is the tide turning against pharmaceutical patentees in Australia?
A pair of recent decisions from the Federal Court of Australia suggest that it may be about to become more difficult for drug patent owners to prevail in requests for interlocutory injunctions.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.